MiRNA 129 has been reported to have great potential as a therapeutic agent in select tumors including bladder cancer [27], colorectal cancer [28], gastric cancer [29], and lung cancer [30], and may inhibits cancer cell proliferation, metastasis and invasion through targeting relevant genes such as ETS1 [31], CDK6 [32], PAK5 [33]. This evidence concerns the gene CDK6 and urinary bladder carcinoma.